- Q3 gross margin 66% v 65% y/y

Other headlines for [VRX]

• VRX 12/30/1899 00:00am
  Valeant Pharmaceuticals International Completes Acquisition of Dow Pharmaceutical Sciences, Inc.- Unit is a privately held dermatology company that specializes in the development of topical products on a proprietary basis, as well as for more...
  
• VRX 12/30/1899 00:00am
  Valeant Pharmaceuticals International Price Target raised to $12 from $9 at Brean Murray, maintains sell rating
  
• VRX 12/30/1899 00:00am
  Valeant Pharmaceuticals International Increases FY08 EPS guidance due to impact of acquisition $0.60-0.80 v $0.21e, FY09 EPS to $1.35-1.60 v $0.93e - filing
  
• VRX 12/30/1899 00:00am
  Valeant Pharmaceuticals International To acquire Dow Pharmaceutical Sciences, Inc. for $285M- The transaction is expected to close at year end. - The transaction significantly enhances Valeant's dermatology franchise in the United more...
  
• VRX 12/30/1899 00:00am
  Valeant Pharmaceuticals International Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsyin Phase III Study- Phase III study demonstrated that the investigational compound more...
  

Healthcare sector headlines

• ROG.SZ Today 06:02am
  Roche Holding AG Plexxikon Enters Second Partnership with Co. To Develop PLX5568 For Polycystic Kidney Disease- The main focus of this partnership will be the development of this small molecule inhibitor of Raf more...
  
• TOPO.DC Today 04:03am
  Topotarget Initiates phase 2 portion of a NCI sponsored study with belinostat given at higher than usual doses for liver cancer- Belinostat can be safely administered in higher doses - Co. begins phase 2 in more...
  
• QMED.SW Today 02:11am
  Q-Med Terminates international distribution agreement with Palomar- Agreement was originally entered back in Jan 2008 - Due to the downturn in the world-wide economic environment, Q-Med''s efforts are more...
  
• AKR.UK Today 02:07am
  Akers Biosciences, Inc. Reaffirms pretax profit in line with prior guidance, expects to report positive net profit- The second half of the year was significantly more profitable than the first, owing largely to the sale of more...
  
• IDMI Today 01:59am
  IDM Pharma Inc Update on Mifamurtide European Regulatory Status